We are thrilled to announce that we have filed our Liraglutide injection (pen) for marketing authorization in China after successful phase I and phase III clinical trials in China in September 2021. The application has been accepted by the NMPA for evaluation, first in China.

 

      In addition, in end of September 2021, our application of Semaglutide injection (pen) for clinical trial permit in China was approved, first and only in China so far.

 

      In Jan. 2021, we had filed Liraglutide API DMF to US FDA.